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a Department of Pharmacology and Pharmacotherapy, Interdisciplinary Excellence Centre, Faculty of Medicine, University of Szeged, Hungary 
b Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Hungary 
c Department of Physiology, Anatomy and Neuroscience, Institute of Biology, Faculty of Science and Informatics, University of Szeged, Hungary   







A B S T R A C T   
The objectives of this study were to investigate the effects of KISS1 94-121 fragment on the contractility of non- 
pregnant and pregnant rat uteri, and to determine the uterine and myometrial expressions of Kiss1r. Uterine 
muscle strips were obtained from non-pregnant Sprague-Dawley rats in oestrous phase and from pregnant rats on 
gestational days 5, 15, 18, 20 or 22. The in vitro contractility measurements were carried out in an isolated organ 
bath in the presence of KISS1 94-121. Experiments with 5-day pregnant tissues were also performed in the 
presence of kisspeptin-234 trifluoroacetate. The mRNA and protein expressions of Kiss1r were measured by RT- 
PCR and Western blot analysis, while localizations of receptors were defined by fluorescent immunohisto-
chemistry. KISS1 94-121 induced a dose-dependent relaxation both in non-pregnant and pregnant intact and 
endometrium-denuded uteri. A gradual decrease was found in the uterine expressions of Kiss1r mRNA and 
protein towards the end of the gestational period, and it was further confirmed by the immunohistochemical 
results. The significant majority of Kiss1r is found in the myometrium, however the few endometrial Kiss1r also 
influences the uterine contractions. The relaxing effect of kisspeptin is continuously reduced towards the end of 
gestational period in parallel with the reduction of Kiss1r expression. Our results suggest a putative role of 
kisspeptin in the maintenance of uterine quiescence that may have significance in miscarriage or preterm 
contractions.   
1. Introduction 
Several neuropeptides regulate uterine smooth muscle contractions. 
The most well-known of them is oxytocin, which plays a key role in 
inducing myometrial contractions at the time of labour (Gimpl and 
Fahrenholz, 2001). Towards parturition, the uterine oxytocin receptors 
are markedly upregulated, therefore the responsiveness of the myome-
trium is intensified (Blanks and Thornton, 2003; Fuchs et al., 1984). 
Despite the controversial studies reporting that maternal plasma con-
centration may vary between individuals, oxytocin serum levels appear 
to gradually increase in most human pregnancies with peak concentra-
tions at birth (De Geest et al., 1985). 
The sensory neuropeptide calcitonin gene-related peptide (CGRP) 
has relaxant effects on different types of smooth muscles. CGRP has been 
shown to inhibit uterine contractions in both human and rat studies 
(Pennefather et al., 1990; Samuelson et al., 1985). CGRP caused 
dose-dependent relaxation of spontaneous and electric field stimulated 
contractions. However, a loss of its action was observed at the end of 
gestation and after delivery (Anouar et al., 1998). 
Nociceptin/orphanin FQ (N/OFQ), a product of the precursor pro-
tein prepronociceptin (PNOC), acts as a natural ligand for the nociceptin 
receptor (NOP) (Meunier et al., 1995; Reinscheid et al., 1995). Besides 
the central effects of N/OFQ (e.g. pain transmission), its functional 
relevance as a neuroendocrine modulator of female reproduction has 
been reported as well (Foradori et al., 2007). The smooth muscle 
relaxant effect of N/OFQ on different types of smooth muscles has been 
well-documented (Meunier, 1997). N/OFQ relaxes rat and human 
myometria. Furthermore, both N/OFQ and its precursor peptide were 
identified in the preterm human myometrium, and in the pregnant rat 
uterus (Deák et al., 2013; Klukovits et al., 2010). PNOC is the precursor 
for nocistatin, which also participates in the regulation of pain modu-
lation, but exerts opposite effects than those of N/OFQ. Its action was 
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proved to be independent of the nociceptin receptor (Okuda-Ashitaka 
and Ito, 2000). The impacts of nocistatin on the function of rat and 
human uteri were also reported. The presence of nocistatin was detected 
in non-pregnant and pregnant rat uterine tissue, with elevated levels on 
the last day of gestation. Results of in vitro contractility studies showed 
that nocistatin exerts contraction-inhibitory effects in the human and rat 
myometrium, and that N/OFQ can enhance this action. Evidence also 
suggests that in rats the relaxant effect of nocistatin is mediated by the 
release of CGRP (Deák, 2013; Deák et al., 2013). 
During the past decades, plenty of information has become available 
on kisspeptin and its potential roles in controlling reproductive biology. 
The products of the KISS1/Kiss1 gene, widely referred to as kisspeptins, 
are derived from a larger inactive precursor peptide composed of 145 
amino acids, which is proteolytically cleaved into shorter, biologically 
active fragments. The largest and most significant cleavage product 
consists of 54 amino acids, and it was first recognized for its anti- 
metastatic activities on human malignant melanoma cell lines in 1996 
(Lee and Welch, 1997; Ohtaki et al., 2001). Through further proteolytic 
processing, other derivates are generated consisting of 10, 13 or 14 
amino acids. All these fragments efficiently activate both rat and human 
kisspeptin receptor GPR54 (Kiss1r), which is coupled to Gq/11 leading to 
phospholipase C activation, hydrolysis of phosphatidylinositol-4, 
5-bisphosphate into inositol-1,4,5-trisphospate (IP3) and diacylglycerol 
(DAG). Then, IP3 mediates Ca2+ mobilization from intracellular stores, 
while DAG formation results in protein kinase C activation, which 
triggers the phosphorylation of different mitogen-activated protein ki-
nases, like ERK1/2 and p38 (Kotani et al., 2001). Expressions of kiss-
peptin and its receptor have been observed in reproductive tissues of 
various species. High levels of mRNA and protein expressions of kiss-
peptin were detected in the syncytiotrophoblast cells of the human 
placenta (Kotani et al., 2001). Elements of the kisspeptin/GPR54 system 
were also identified in the ovaries and the uterus of both humans and 
rodents, as well as in other organs of the human female genital tract 
(Castellano et al., 2006; Cejudo Roman et al., 2012; Gaytán et al., 2009; 
Zhang et al., 2014). Kisspeptin acts as a potent upstream regulator of 
GnRH release, and therefore induces LH and FSH secretion, regulates 
pubertal development and fertility (Han et al., 2005; Roa et al., 2008). 
The direct stimulatory effect on gonadotropin secretion is through the 
activation of GPR54 coexpressed in most GnRH neurons in the hypo-
thalamus. However, possible indirect actions of kisspeptin via 
GABAergic/glutamatergic transmissions are also suspected (Pieleck-
a-Fortuna et al., 2008). In late pregnancy, kisspeptin is able to increase 
the firing activity of oxytocin neurons, however, the exact mechanism 
and function of this action are still not clear (Scott and Brown, 2011). 
Since among the neuropeptides there is no data available regarding 
the direct involvement of kisspeptin in uterine contractility, our aim was 
to investigate the effects of this neuropeptide on the contractions of non- 
pregnant and pregnant rat uteri. We also measured the uterine expres-
sions of Kiss1r and defined their localization during pregnancy and in 
non-pregnant samples. 
2. Materials and methods 
2.1. Housing and handling 
The animals were treated in accordance with the European Com-
munities Council Directive (2010/63/EU) and the Hungarian Act for the 
Protection of Animals in Research (Article 32 of Act XXVIII). All ex-
periments involving animal subjects were carried out with the approval 
of the National Scientific Ethical Committee on Animal Experimentation 
(registration number: IV./3071/2016.). The animals were housed in 
rooms with controlled temperature (22 ± 3 ◦C), humidity (30%–70%), 
and light (12 h light/dark cycle), with tap water and standard rodent 
pellet (Animalab Hungary Ltd, Vác, Hungary) available ad libitum. 
2.2. Mating of the animals, selection of non-pregnant females 
Sexually mature Sprague-Dawley rats (Animalab Hungary Ltd, Vác, 
Hungary) were mated in a special mating cage in the early morning 
hours. Female (180-220 g) and male (220-260 g) rats were separated 
with a time-controlled metal door, which was opened before dawn (5.00 
a.m.). About 3-4 h after possible mating, vaginal smears were taken from 
the female rats and checked under microscope at 1200x magnification. 
Pregnancy was confirmed by the presence of spermatozoa in the sample 
or sperm plug in the vagina. The day of copulation was designated as 
first day of pregnancy. Non-pregnant fertile female rats in oestrous 
phase were also used. The oestrous cycle was detected on the day of the 
experiment by vaginal impedance measurement with Oestrus Cycle 
Monitor (Fine Science Tools, Foster City, CA), and rats with impedance 
values between 7-9 kΩ were chosen for the experiments. 
2.3. In vitro contractility studies 
2.3.1. Uterus preparation 
On the day of the experiment, the animals were terminated by car-
bon dioxide inhalation. Uteri were removed from non-pregnant rats in 
oestrous phase or from pregnant rats on gestational days 5, 15, 18, 20 or 
22. Uterine tissues were then prepared for the in vitro contractility 
measurements. Briefly, two rings were sliced from the middle part of 
each horn (4 rings from 1 rat), including implantation sites in case of 
pregnancy, and then immediately placed in a Petri dish containing de 
Jongh solution (137 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 12 
mM NaHCO3, 4 mM Na2HPO4, and 6 mM glucose [pH 7.40]). Carbogen 
(95% oxygen and 5% carbon dioxide) was bubbled through the buffer 
and its temperature was maintained at 37 ◦C. The muscle rings previ-
ously cleaned of fat and connective tissue were mounted vertically in the 
isolated organ bath under the same conditions described before. After 
mounting, the initial resting tension was set at about 1.5 g, and the strips 
were equilibrated for at least 45 min, with a buffer change every 15 min. 
Uterine contractions were then elicited with 25 mM KCl. When the 
response became stable (about 5-7 min), rhythmic contractions were 
recorded for 5 min after each dose of kisspeptin. 
2.3.2. Removal of the endometrium 
The experiments with nonpregnant and pregnant rats were also 
carried out in the absence of the endometrium. After turning the uterine 
tissue inside out, the endometrial layer was removed by gentle scraping 
with a non-sharp blade to leave the muscle layers intact. 
2.3.3. Kisspeptin studies 
Cumulative concentrations of the KISS1 94-121 fragment (Sigma- 
Aldrich Kft., Budapest, Hungary) were added to each chamber of the 
organ bath (10 ml) in the concentration range of 10-12–10-7 M, and 5- 
min periods were recorded. The stock solution of kisspeptin was pre-
pared with distilled water and it was stored at -20 ◦C. The working di-
lutions were made just before the start of the experiment. The tension of 
the myometrial rings was measured with a strain gauge transducer (SG- 
02; MDE GmbH., Walldorf, Germany) and recorded and analysed with 
the SPEL Advanced ISOSYS Data Acquisition System (MDE GmbH, 
Walldorf, Germany). The areas under curves of 5-min periods were 
evaluated, and the effects of KISS1 94-121 were expressed as a per-
centage of the KCl-induced contractions. The concentration-response 
curves were plotted and the concentration for 50% of the maximum 
effect (EC50) and the maximum contraction-inhibiting value (Emax) were 
calculated. Experiments with 5-day pregnant tissues were also per-
formed in the presence of kisspeptin-234 trifluoroacetate (Sigma- 
Aldrich Kft., Budapest, Hungary), an antagonist of Kiss1r. 
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2.4. RT-PCR and Western blot studies 
2.4.1. Tissue isolation 
After the termination of the rats, the uterine tissues from non- 
pregnant and pregnant animals (n = 6) were rapidly removed and 
placed into RNAlater Solution (Sigma-Aldrich, Budapest). The tissues 
were frozen in liquid nitrogen and stored at -75 ◦C until the extraction of 
total RNA. 
2.4.2. Total RNA preparation 
Total cellular RNA was isolated by extraction with guanidinium 
thiocyanate-acid-phenol-chloroform according to the procedure of 
Chomczynski and Sacchi (2006). After precipitation with isopropanol, 
the RNA was washed with 75% ethanol and then re-suspended in diethyl 
pyrocarbonate-treated water. RNA purity was controlled at an optical 
density of 260/280 nm with BioSpec Nano (Shimadzu, Kyoto, Japan); all 
samples exhibited an absorbance ratio in the range of 1.6-2.0. RNA 
quality and integrity were assessed by agarose gel electrophoresis. 
2.4.3. Real-time quantitative reverse-transcriptase PCR 
Reverse transcription and amplification of the PCR products were 
performed by using the TaqMan RNA-to-CT-Step One Kit (Life Tech-
nologies, Budapest, Hungary) and an ABI StepOne Real-Time cycler. 
Reverse-transcriptase PCR amplifications were performed as follows: at 
48 ◦C for 15 min and at 95 ◦C for 10 min, followed by 40 cycles at 95 ◦C 
for 15 sec and at 60 ◦C for 1 min. The generation of specific PCR products 
was confirmed by melting curve analysis. The following primers were 
used: assay ID Rn00576940_m1 for Kiss1r water channel and 
Rn00667869_m1 for β-actin as endogenous control. All samples were 
run in triplicates. The fluorescence intensities of the probes were plotted 
against PCR cycle number. The amplification cycle displaying the first 
significant increase of the fluorescence signal was defined as the 
threshold cycle (CT). 
2.4.4. Western blot analysis 
25 μg of sample protein per well was subjected to electrophoresis on 
4-12% NuPAGE Bis-Tris Gel in XCell SureLock Mini-Cell Units (Life 
Technologies, Hungary). Proteins were transferred from gels to nitro-
cellulose membranes using the iBlot Gel Transfer System (Life Tech-
nologies). The blots were incubated on shaker with Kiss1r and β-actin 
polyclonal antibodies (Bioss Antibodies, Massachusetts, 1:200) in 
blocking buffer. Antibody binding was detected with the Western 
Breeze® Chromogenic immunodetection kit (ThermoFisher Scientific, 
Hungary). Images were captured with the EDAS290 imaging system 
(Csertex Ltd., Budapest, Hungary), and the optical density of each 
immunoreactive band was determined with Kodak 1D Images analysis 
software. 
2.5. Immunohistochemistry 
2.5.1. Tissue collection 
After the termination of the rats, the uterine and myometrial samples 
taken for immunohistochemical studies were embedded in cryomatrix 
medium (Shandon Cryomatrix, Thermo Scientific), snap-frozen by sub-
merging in liquid nitrogen and then stored at -20 ◦C. 
2.5.2. Fluorescent immunohistochemistry 
The dissected tissue samples of the uterus were processed for fluo-
rescent microscopy. For fluorescent immunohistochemistry, 5 μm-thick 
cryosections were prepared from different days of gestation. After 
washing in TBS with 0.025% Triton X-100 and blocking in TBS con-
taining 1% bovine serum albumin (Sigma-Aldrich, Budapest, Hungary) 
and 10% normal goat serum (Sigma-Aldrich, Budapest, Hungary) (2 h, 
room temperature), the samples were incubated overnight with anti- 
Kiss1r (rabbit; Alomone Labs, Jerusalem, Israel; final dilution 1:50) 
primary antibody at 4 ◦C. After washing in TBS, samples were incubated 
with anti-rabbit Alexa Fluor 488 (Life Technologies Corporation, Mo-
lecular Probes, Inc., Eugene, OR; final dilution 1:200) secondary anti-
body for 1 h at room temperature. Negative controls were performed by 
omitting the primary antibody when no immunoreactivity was 
observed. Sections were mounted in Fluoroshield TM with DAPI 
mounting medium (Sigma-Aldrich, Budapest, Hungary), observed and 
photographed with a Zeiss Imager Z.2 fluorescent microscope equipped 
with an Axiocam 506 mono camera. 
2.6. Statistical analysis 
The statistical analysis for each experiment was carried out with 
ANOVA using Tukey’s post hoc test by Prism 5.01 (GraphPad Software, 
San Diego, CA). 
3. Results 
3.1. In vitro contractility measurements 
In non-pregnant and pregnant uteri, KCl elicited rhythmic contrac-
tions and KISS1 94-121 modified these contractions (Fig. 1). 
3.1.1. Effects of KISS1 94-121 on non-pregnant uterine and myometrial 
contractions 
The KISS1 94-121 fragment relaxed the KCl-stimulated rhythmic 
contractions of non-pregnant uteri with or without endometrium in a 
concentration-dependent manner in the range of 10-12 to 10-7 M (Fig. 2A 
and 2B). In the non-pregnant and endometrium-denuded myometrium, 
the calculated maximal relaxation was more than 10% higher in com-
parison to the intact uterus (Table 1). The EC50 value of KISS1 94-121 
was shifted to the left in the denuded myometrium as compared with 
the uterus. 
3.1.2. Effects of KISS1 94-121 on pregnant uterine and myometrial 
contractions 
Contractility studies were performed on uterine and myometrial 
rings obtained from 5, 15, 18, 20 and 22-day pregnant rats. KISS1 94- 
121 relaxed the pregnant uterine smooth muscles in a dose-dependent 
manner. The mean maximal relaxation of KISS1 94-121 gradually 
decreased up to the day of delivery (Fig. 2A, Table 1). The most potent 
uterorelaxant action was measured on gestational day 5. However, its 
relaxant effect was still detectable on the last day of pregnancy (day 22). 
Although the EC50 values of KISS 94-124 numerically changed during 
the gestational period, these changes were not significant. 
Contrary to the measurements with intact uteri, in the denuded 
myometrial samples we did not find a gradually declining tendency in 
the relaxing effect of KISS1 94-121 (Fig. 2B). A significant decrease in 
the maximum effect was found on the 18th and 22nd days of gestation, 
while a transient increase was found on day 20. The comparison of 
uterine and myometrial relaxations showed that KISS1 94-121 was more 
effective at the end of pregnancy when the endometrium was removed, 
although the difference between the Emax values was only significant on 
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Fig. 1. Representative records of KCl-induced uterine contractions and the cumulative effects of KISS1 94-121 on non-pregnant (A) and pregnant (B-F) uteri. Each 
case KISS1 94-121 elicited a relaxing effect. 
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day 20 of gestation. The 10-8 M concentration of KISS1 94-121 practi-
cally elicits the maximum relaxing effect. 
3.1.3. Kisspeptin studies in the presence of a Kiss1r antagonist 
To confirm that KISS1 94-121 action is mediated via Kiss1r, 
contractility studies were performed in the presence of kisspeptin-234 
Fig. 2. Effects of KISS1 94-121 in the range of 10-12 to 10-7 M on KCl-evoked 
contractions of the non-pregnant and pregnant rat uterus (A) or 
endometrium-denuded myometrium (B). Cumulative concentrations of KISS1 
94-121 caused smooth muscle relaxation in each case. The change in contrac-
tion was calculated via the area under the curve and expressed in % ± S.E.M., n 
= 6 for each group. 
Table 1 
The EC50 and Emax values calculated from the dose-response curves demon-
strated in Fig. 1A and 1B. Uterine and endometrium-denuded myometrial Emax 
and EC50 were compared to each other. Also, day 5 was compared to non- 
pregnant values, and each investigated day of pregnancy was compared to the 
previous gestational day. Statistical analysis was carried out with one-way 
ANOVA with Tukey’s test for post-hoc analysis. ns: not significant, a: P <
0.05, b: P < 0.01, c: P < 0.001.  
EC50 (M ± S.E.M.)  










































Emax (% ± S.E.M.)  
Uterus Myometrium Uterus compared with 
myometrium 
non-pregnant 34.1 ± 2.0 45.3 ± 1.8 a 
day 5 of 
gestation 
50.3 ± 2.3b 41.7 ± 1.7 ns ns 
day 15 of 
gestation 
44.1 ± 1.8 ns 47.3 ± 1.4 ns ns 
day 18 of 
gestation 
40.4 ± 1.6 ns 31.8 ± 1.8c ns 
day 20 of 
gestation 
37.5 ± 1.4 ns 46.6 ± 1.1c c 
day 22 of 
gestation 
27.4 ± 1.2a 30.7 ± 1.5c ns  
Fig. 3. Effects of KISS1 94-121 (10-12 to 10-7 M) in the presence of kisspeptin- 
234 trifluoroacetate (Kissr1 antagonist) on KCl-evoked contractions on 5-day 
pregnant rat uterus. Kisspeptin-234 trifluoroacetate reduced the maximum ef-
fect of KISS1 94-121. The change in contraction was calculated via the area 
under the curve and expressed in % ± S.E.M., n = 6 for each group. 
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trifluoroacetate (Kiss1r antagonist) on 5-day pregnant uteri. The effect 
of KISS1 94-121 was significantly inhibited, its maximum effect was 
reduced by 40%. However, the reduction in the calculated maximal 
relaxation was significant only in the case of 5-day pregnant uterus 
(Fig. 3, Table 2). 
3.2. RT-PCR and Western blot studies 
3.2.1. Kiss1r mRNA expressions in non-pregnant and pregnant uterus and 
myometrium 
Both the uterine (Fig. 4. full columns) and myometrial (Fig. 4. empty 
columns) mRNA expressions of Kiss1r were determined. Kiss1r mRNA 
was found both in non-pregnant and pregnant uterine tissues. The 
highest levels of Kiss1r mRNA were found in the non-pregnant and the 5- 
day pregnant uteri. Towards the end of pregnancy, Kiss1r mRNA levels 
were dramatically reduced, reaching the lowest value on gestational day 
15. Although a slight elevation was found on gestational day 18, further 
alterations were not detected, and the Kiss1r mRNA level remained low 
till the day of delivery. The removal of the endometrium caused a pro-
portional decrease in the amount of receptor mRNA on each investigated 
gestational day as well as in non-pregnant samples, although the change 
was significant only in the case of non-pregnant myometria. 
3.2.2. Kiss1r protein expressions in non-pregnant and pregnant uterus and 
myometrium 
The highest Kiss1r protein levels were measured in the non-pregnant 
tissues (Fig. 5). We also observed a high optical density on the 5th day of 
pregnancy both in uteri (full columns) and denuded myometria (empty 
columns). Kiss1r protein levels declined towards the end of the gesta-
tional period, although the decrease was not significant after gestational 
Table 2 
EC50 and Emax values calculated from the dose-response curves demonstrated in 
Fig. 2. The Emax and EC50 of KISS1 94-121 were compared to its action in the 
presence of the antagonist. Statistical analysis was carried out with one-way 
ANOVA with Tukey’s test for post-hoc analysis. ns: not significant, c: P < 0.001.   
EC50 (M ± S.E.M.) Emax (% ± S.E.M.) 
5-day pregnant uterus 2.1x10-10 ± 3.3x10-10 49.0 ± 3.1 
5-day pregnant uterus+antagonist 1.5x10-10 ± 1.0x10-10 ns 29.1 ± 3.1c  
Fig. 4. Changes in the uterine (full columns) and myometrial (empty columns) mRNA expressions of Kiss1r throughout gestation and in non-pregnant samples. The 
expression was significantly lower in late-pregnant rat uteri. Kiss1r expression in the uterus was compared to the myometrial expression on each gestational day as 
well as in non-pregnant samples (+). Also, day 5 was compared to the non-pregnant values, and each investigated day of pregnancy was compared to the previous 
gestational day (* and #). Statistical analysis was carried out with one-way ANOVA with Tukey’s test for post-hoc analysis. np: non-pregnant, np_m: non-pregnant 
(denuded) myometrium, +: P < 0.05, ###: P < 0.001, ***: P < 0.001, n = 4 for each group. 
Fig. 5. The uterine (full columns) and denuded myometrial (empty columns) 
protein expression of Kiss1r on different days of gestation and in non-pregnant 
samples along with representative blots. Kiss1r expressions show a declining 
trend throughout pregnancy as compared to the previous day in uteri (*) or 
denuded myometria (#). The results in the uterus were also compared to the 
myometrial expressions on each gestational day as well as in non-pregnant 
samples. Statistical analysis was carried out with one-way ANOVA with 
Tukey’s test for post-hoc analysis. np: non-pregnant uterus, np_m: non-pregnant 
(denuded) myometrium, ***: P < 0.001, ##: P < 0.01, ###: P < 0.001, n = 4- 
7 for each group. 
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day 15. The removal of the endometrium caused a proportional decrease 
in Kiss1r levels in all myometria, but these changes were not significant. 
3.3. Immunostaining of Kiss1r 
A strong immunoreactivity of Kiss1r was observed both in pregnant 
and non-pregnant rat uterine samples. Generally, the most intensive 
Kiss1r immunostaining was detected in the longitudinal layer of the 
myometrium, a less intense staining was found in the circular layer of 
the myometrium, while the weakest staining was found in the endo-
metrial layer, although Kiss1r is also highly expressed in vascular 
smooth muscle cells. The highest intensities were found in the non- 
pregnant and the 5-day pregnant uteri. Gradually descending Kiss1r 
immunoreactivities were found towards the last day of pregnancy (day 
22), both in myometrial and endometrial layers, but the reduction was 
especially spectacular in the endometrial layers. From day 18, immu-
nostaining was primarily localized in the muscle layers of the uterus, 
while the endometrial activities became negligible. The staining in-
tensity of 22-day pregnant uteri was marginal compared to the non- 
pregnant or 5-day pregnant samples (Fig. 6). 
4. Discussion 
Several neuropeptides have been shown to affect smooth muscle 
function, but only a few studies have investigated the local effects of 
these peptides in the uterus. Although kisspeptin and Kiss1r were 
identified in uterine tissue (Castellano et al., 2006; Cejudo Roman et al., 
2012; Gaytán et al., 2009; Zhang et al., 2014), no data has been available 
about the role of kisspeptin in uterine contractions. Therefore, the main 
objective of this study was to determine the role of kisspeptin in uterine 
activity through the gestational period in rats. 
In the contractility studies, KISS1 94-121 fragment was used to elicit 
kisspeptin action. This 28-amino-acid fragment has very high affinity to 
Kiss1r (Muir et al., 2001) with a much better stability than the other 
shorter fragments of kisspeptin (Kirby et al., 2010). Additionally, its 
water solubility is also good, therefore it was proper for the organ bath 
contractility measurements. We found that KISS1 94-121 inhibited the 
contractions both in non-pregnant and pregnant uteri in a 
dose-dependent manner. The uterine effect of KISS1 94-121 was also 
measured in the presence of a specific Kiss1r antagonist. The measure-
ment was carried out on 5-day pregnant samples because the relaxing 
effect of KISS1 94-121 was the highest on that gestational day. We 
proved that the contraction inhibitory action of KISS1 94-121 can be 
diminished by the specific inhibitor of Kiss1r, therefore we can be sure 
that the relaxing effect is really mediated through Kiss1r. 
The relaxing effect of KISS1 94-121 was the strongest in non- 
pregnant and early pregnant (day 5) uteri, while towards the end of 
gestation its inhibitory effect was gradually decreased, reaching the 
lowest value on the last day of pregnancy (day 22). A similar decrease 
was found in the expressions of Kiss1r mRNA and protein in non- 
pregnant and early pregnant samples towards the end of the gesta-
tional period. The same phenomenon can be confirmed by the immu-
nohistochemical results, which reveal the reduced intensity of 
immunostaining in all layers of the uterus as the end of the gestational 
period approached. Considering the fact that rat uterine tissue has a low 
connective tissue content (less than 6%) and the hormonal changes 
Fig. 6. Representative fluorescent micrographs of cryosections from the uterus of non-pregnant rat (A), and on gestational days 5 (B), 15 (C), 18 (D), 20 (E) and 22 
(F) after Kiss1r immunohistochemistry (green). DAPI was used to label the cell nuclei (blue). P: perimetrium, ML: longitudinal layer of myometrium, MC: circular 
layer of myometrium, E: endometrium, arrow: large blood vessel in the stratum vasculare. 
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towards the end of pregnancy furtherly reduce its amount (Bieńkiewicz 
et al., 1996), it can be stated that the connective tissue mass is marginal 
as compared with that of smooth muscles. Since no data is available 
about the Kiss1r expression in any connective tissue (and its probability 
is very low), we suppose that the immunostaining revealed the Kiss1r 
expression in the smooth muscle of the non-pregnant and pregnant rat 
uteri. This is also supported by the high-resolution images where the 
stained Kiss1r are clearly located in both circular and longitudinal 
smooth muscle layers. Although our immunostaining study was not 
quantitative, the differences among the non-pregnant or 5-day pregnant 
and 22-day pregnant samples are spectacular. The most intense Kiss1r 
staining was seen on the non-pregnant tissues, whereas the lowest re-
ceptor expression was found on the last gestational day, when staining 
was practically detected only in the myometrial layer. In general, the 
receptors were predominantly located in the longitudinal, then in the 
circular myometrial muscle layers, and the weakest expression was 
found in the endometrium. It was also proved by the removal of the 
endometrium that it did not significantly modify the expression of Kiss1r 
protein on any gestational day or even in non-pregnant uteri. These 
suggest that Kiss1r is mostly a myometrial receptor participating directly 
in the control of uterine smooth muscle contractions as a relaxing 
mechanism. This is corroborated by the findings that the highest ex-
pressions of Kiss1r were found in non-pregnant and 5-day pregnant 
samples. The contractility of the non-pregnant uterus is usually low in 
rats (Ducza et al., 2009), while the 5th gestational day is considered as 
the time of embryo implantation in rats (Garcia et al., 2017), which 
requires relative quiescence in the uterine activity. 
Surprisingly, KISS1 94-121 exerted a more potent uterorelaxant ef-
fect in the non-pregnant and 20-day pregnant uteri without the endo-
metrial layer. Additionally, significant reduction was found in mRNA 
level of Kiss1r after denuding the non-pregnant uteri. Furthermore, the 
removal ceased the gradual decreasing tendency in the relaxing effect of 
KISS1 94-121, suggesting the importance of the almost non-significant 
endometrial Kiss1r in the contractile response of the pregnant uterus 
(their expressions were so low that the Western blot study could not 
detect significant differences between the uterine and denuded myo-
metrial pregnant samples on any gestational days and even in the non- 
pregnant samples as well). These findings might suggest that a 
currently unknown mechanism (maybe networking with other receptors 
or endometrial secretory responses) can be involved in the Kiss1r 
pathway modulating uterine contractility. The vital role of the endo-
metrial layer in the control of uterine contractility was already 
demonstrated by the local production of different agents affecting 
smooth muscle function (Kothencz et al., 2018). A networking is already 
proved with kisspeptin neurons in the central nervous system (Arthur 
et al., 2008) and the reproductive organs (D’Occhio et al., 2020), but no 
data is available for the uterine smooth muscle in this respect. 
In summary, our results suggest that Kiss1r mediates a relaxing effect 
in the non-pregnant and pregnant rat uterus. As the demand for more 
intensive contractions is increased towards the end of pregnancy, the 
expression of Kiss1r is gradually decreased, indicating its role in the 
maintenance of uterine quiescence during pregnancy. The modified re-
sponses of denuded myometria suggest that endometrial Kiss1r might 
have some networking with other mechanisms for uterine relaxations. 
These putative mechanisms must be revealed in further studies. The 
maintenance of the activation of Kiss1r during pregnancy might reduce 
the risk of miscarriage or premature contractions and could serve as a 
new drug target for obstetrics in the future. 
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Klukovits, A., Tekes, K., Gündüz Çinar, Ö., Benyhe, S., Borsodi, A., Deák, B.H., Hajagos- 
Tóth, J., Verli, J., Falkay, G., Gáspár, R., 2010. Nociceptin inhibits uterine 
contractions in term-pregnant rats by signaling through multiple Pathways1. Biol. 
Reprod. 83, 36–41. https://doi.org/10.1095/biolreprod.109.082222. 
Kotani, M., Detheux, M., Vandenbogaerde, A., Communi, D., Vanderwinden, J.M., Le 
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